Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report

被引：13

作者：

Arias Ron, David ^{[1
]}

Labandeira, Carmen M. ^{[2
]}

Areses Manrique, Maria Carmen ^{[1
]}

Sampedro Domarco, Paula ^{[1
]}

Abdulkader, Ihab ^{[3
]}

Garcia-Mata, Jesus ^{[1
]}

Rolfo, Christian ^{[4
]}

Gonzalez-Rivas, Diego ^{[5
,6
]}

Luis Firvida, Jose ^{[1
]}

机构：

[1] Univ Hosp Complex Ourense, Med Oncol Dept, Orense, Spain

[2] Hosp Alvaro Cunqueiro, Neurol Dept, Univ Hosp Complex Vigo, Pontevedra, Spain

[3] Univ Hosp Complex Santiago de Compostela, Anatomopathol Dept, Santiago De Compostela, Spain

[4] Univ Maryland, Thorac Med Oncol, Early Clin Trials, Marlene & Stewart Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA

[5] Hosp San Rafael, Thorac Surg Dept, Coruna, Spain

[6] Shanghai Pulm Hosp, Dept Thorac Surg, Shanghai, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2019年 / 9卷

关键词：

squamous lung cancer; nivolumab; leptomeningeal carcinomatosis; PD-L1; complete response; BRAIN METASTASES; 1ST-LINE CHEMOTHERAPY; OPEN-LABEL; DOCETAXEL; NSCLC; VINORELBINE; ERLOTINIB; SURVIVAL; EFFICACY; OUTCOMES;

D O I：

10.3389/fonc.2019.00819

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In a patient who had been diagnosed of located squamous cell lung carcinoma, pneumonectomy, and adjuvant chemotherapy were performed. Brain recurrence and subsequent lung metastatic disease were uncontrolled by neurosurgery, holocranial radiotherapy, and first-line chemotherapy. In August 2015, appearance of leptomeningeal carcinomatosis triggered severe clinical deterioration and threatened the patient's life. Anti-PD1 immune checkpoint inhibitor Nivolumab was initiated in an attempt to stop tumor growth, achieving a spectacular brain and pulmonary complete response and clinical improvement, without serious adverse effects. High expression PD-L1 level (100%) was found in the pathological tissue sample. Nivolumab was maintained for more than 2 years and stopped in December 2017 after 28 months of treatment, with no disease evidence. More than 3 years after its onset, the patient maintains an outstanding PS with complete tumor response and no evidence of disease in last surveillance CT scan and brain MRI.

引用

页数：8

共 35 条

[11] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[12] Leptomeningeal metastases in non-small-cell lung cancer [J].

Cheng, Haiying ;

Perez-Soler, Roman .

LANCET ONCOLOGY, 2018, 19 (01) :E43-E55

[13] Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases [J].

Dudnik, Elizabeth ;

Yust-Katz, Shlomit ;

Nechushtan, Hovav ;

Goldstein, Daniel A. ;

Zer, Alona ;

Flex, Dov ;

Siegal, Tali ;

Peled, Nir .

LUNG CANCER, 2016, 98 :114-117

[14] Do immune checkpoint inhibitors need new studies methodology? [J].

Ferrara, Roberto ;

Pilotto, Sara ;

Caccese, Mario ;

Grizzi, Giulia ;

Sperduti, Isabella ;

Giannarelli, Diana ;

Milella, Michele ;

Besse, Benjamin ;

Tortora, Giampaolo ;

Bria, Emilio .

JOURNAL OF THORACIC DISEASE, 2018, 10 :S1564-S1580

[15] Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases [J].

Flippot, Ronan ;

Biondani, Pamela ;

Auclin, Edouard ;

Xiao, Dingyu ;

Hendriks, Lizza ;

Le Rhun, Emilie ;

Leduc, Charlotte ;

Beau-Faller, Michele ;

Gervais, Radj ;

Remon, Jordi ;

Adam, Julien ;

Planchard, David ;

Lavaud, Pernelle ;

Naltet, Charles ;

Caramella, Caroline ;

Le Pechoux, Cecile ;

Lacroix, Ludovic ;

Gazzah, Anas ;

Mezquita, Laura ;

Besse, Benjamin .

JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (08) :1400-1407

[16] Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens [J].

Fossella, FV ;

DeVore, R ;

Kerr, RN ;

Crawford, J ;

Natale, RR ;

Dunphy, F ;

Kalman, L ;

Miller, V ;

Lee, JS ;

Moore, M ;

Gandara, D ;

Karp, D ;

Vokes, E ;

Kris, M ;

Kim, Y ;

Gamza, F ;

Hammershaimb, L .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (12) :2354-2362

[17] Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib [J].

Gainor, Justin F. ;

Sherman, Carol A. ;

Willoughby, Kathryn ;

Logan, Jennifer ;

Kennedy, Elizabeth ;

Brastianos, Priscilla K. ;

Chi, Andrew S. ;

Shaw, Alice T. .

JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (02) :232-236

[18] Intracerebral efficacy and tolerance of nivolumab in non small-cell lung cancer patients with brain metastases [J].

Gauvain, Clement ;

Vauleon, Enora ;

Chouaid, Christos ;

Lerhun, Emilie ;

Jabot, Laurence ;

Scherpereel, Arnaud ;

Vinas, Florent ;

Cortot, Alexis Benjamin ;

Monnet, Isabelle .

LUNG CANCER, 2018, 116 :62-66

[19] Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient [J].

Gion, Maria ;

Remon, Jordi ;

Caramella, Caroline ;

Soria, Jean-Charles ;

Besse, Benjamin .

LUNG CANCER, 2017, 108 :72-74

[20] Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small Cell Lung Cancer [J].

Haratani, Koji ;

Hayashi, Hidetoshi ;

Chiba, Yasutaka ;

Kudo, Keita ;

Yonesaka, Kimio ;

Kato, Ryoji ;

Kaneda, Hiroyasu ;

Hasegawa, Yoshikazu ;

Tanaka, Kaoru ;

Takeda, Masayuki ;

Nakagawa, Kazuhiko .

JAMA ONCOLOGY, 2018, 4 (03) :374-378

← 1 2 3 4 →